Schering-Plough wins an EC approval

Schering-Plough says the EC has approved Bridion (sugammadex) injection, "the first and only selective relaxant binding agent and the first major pharmaceutical advance in the field of anesthesia in two decades." Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.